The last decade has witnessed impressive advances in our knowledge of human immunodeficiency virus (HIV-1) biology and has resulted in the discovery and clinical application of potent antiviral agents that target virus-encoded proteins. In contrast, progress in developing effective vaccines against HIV-1 has been frustratingly slow. Ideally, an effective HIV-1 vaccine should prevent the development of disease following infection with a variety of virus isolates and be effective for extended periods following vaccination. Unfortunately, vaccines consisting of inactivated virus particles, purified viral proteins, or replication-competent vectors expressing HIV or simian immunodeficiency virus (SIV) proteins have not consistently fulfilled these requirements in either the HIV-1/chimpanzee or the SIV/macaque monkey model system. In many cases, immunization with such vaccines failed to generate significant protection even though strong antiviral immune responses could be detected (4, 9, 11, 19, 39, 43, 47, 53, 54, 57) . In successful vaccination experiments, the absence of detectable challenge virus (5, 15, 17, 22, 23, 26, 27, 29, 42) or significant reduction of challenge virus loads or delays in the onset of immunodeficiency (2, 7, 13, 21, 24, 25, 28, 36, 48) has been reported. With few exceptions (15, 42) , however, the challenge virus was inoculated shortly after the last immunization or at the peak of the vaccine-induced immune response (2, 5, 7, 13, 17, 21-29, 36, 48) . The challenge virus and vaccines assayed were frequently homologous or very closely related to one another (2, 5, 7, 13, 15, 17, 22-29, 36, 42) , although some exceptions have been reported (21, 48) . Furthermore, the protective effects measured waned as the time interval between the final vaccine boost and virus challenge lengthened, even when a previously efficacious vaccine was retested (17) .
Although live, attenuated vaccines have been widely used for prophylaxis against diseases induced by other viral and bacterial agents, their potential use for protection of humans against HIV-1 has been controversial because of safety concerns. Nonetheless, it has been repeatedly demonstrated that macaques or chimpanzees persistently infected with nonpathogenic or genetically engineered attenuated isolates of SIV or HIV-1, respectively, strongly resist a subsequent challenge with homologous virus (3, 10, 31-33, 58, 40, 54, 55) or heterologous virus (8, 16, 20, 41, 44, 52) . The duration of protective immunity induced by the continuous replication of nonpathogenic primate lentiviruses has been reported to be at least 2 years (10, 31) . At present, no consensus exists about correlates of protection associated with attenuated lentivirus vaccines, although a role for humoral immunity was suggested from a study in which sera from vaccinated animals conferred protection following passive transfer (8) . In this study, the protective capacity of live, attenuated SIV strains against a highly heterologous challenge virus was rigorously assessed.
MATERIALS AND METHODS
Attenuated SIVs. SIV⌬2 and SIV⌬3 (Fig. 1) are previously described attenuated derivatives of SIV mac239 (12, 37, 61) . Both viruses carry a 182-bp deletion in nef and a 172-bp deletion in the upstream U3 region of the long terminal repeat (LTR). SIV⌬3 has an additional 101-bp deletion in vpr. Three rhesus macaques were intravenously inoculated with cell-free SIV⌬3 (monkey 7887) or SIV⌬2 (monkeys 42582 and 43982) prepared in human T-cell line CEMx174 4 years prior to challenge with the SIV/HIV chimeric construct (SHIV). All three animals had become SIV seropositive without showing any signs of clinical or immunological abnormalities. None of the three animals had been used for any other experiments.
Challenge SHIV. SHIV MD1 ( Fig. 1 ) (51), used for the challenge, contains a portion of the U3 LTR, the R-U5 LTR, gag, pol, vif, and vpx, and the first 17 codons of vpr of SIV mac239 . The tat, rev, env, and nef genes, the remainder of vpr, and a portion of the U3 LTR are derived from HIV-1; most of the HIV-1 sequences were of HIV-1 DH12 (49) origin except for small segments at SIV-HIV-1 junctions (145 bp in vpr; 27 bp in nef) that were derived from HIV-1 NL43 (1). SHIV MD1 does not express the vpu gene because it lacks an AUG translation initiation codon (49) . The animal challenge stock was generated by in vivo and in vitro passages: a cynomolgus macaque (S2407) was inoculated with the cloned SHIV MD1 ; 21 weeks later, 5 ml of blood from animal S2407 was transfused into a second cynomolgus monkey (4138). Animal S2407 had already lost most of its CD4 cells by week 21 and subsequently died with AIDS on week 63 (51) . Virus was isolated from peripheral blood mononuclear cells (PBMC) of animal 4138 1 week following the blood transfusion and was passaged a single time in cultured rhesus macaque PBMC to generate the challenge stock used in this vaccine study. One milliliter of the SHIV MD1 stock contains 6 ϫ 10 4 of a 50% tissue culture infectious dose (TCID 50 ), as assayed in the human MT-4 T-cell line, and 11 ng of p27 gag antigen, as measured by SIV core antigen assay (Coulter, Hialeah, Fla.). Sequenced molecular clones derived from the challenge stock contained approximately 10 to 20 amino acid substitutions in env and scattered changes in other genes compared to the original SHIV MD1 (56) .
Animals. Rhesus macaques (Macaca mulatta) tested negative for SIV, simian type D retrovirus, and simian T-cell lymphotropic viruses before use. All animal care and use procedures conformed to the Public Health Service Policy on Humane Care and Use of Laboratory Animals.
Virus isolation from PBMC of infected animals. Macaque PBMC were purified from acid-citrate-dextrose-treated whole blood by Ficoll-Hypaque (Pharmacia, Piscataway, N.J.) density gradient centrifugation, and 2 ϫ 10 6 cells were depleted of CD8-positive cells by using CD8 antibody-conjugated magnetic beads (Miltenyi Biotec, Sunnyvale, Calif.). The CD8-depleted cells were mixed with 10 6 normal macaque PBMC, stimulated with 1 g of phytohemagglutinin (PHA) per ml for 3 days, and cultured for 4 weeks in RPMI 1640 medium supplemented with 10% fetal bovine serum (HyClone, Logan, Utah), gentamicin (50 g/ml; Whittaker), penicillin (50 U/ml)-streptomycin (50 g/ml) (Gibco-BRL), and recombinant human interleukin-2 (20 U/ml; Boehringer Mannheim, Indianapolis, Ind.); fresh, PHA-stimulated macaque PBMC were added on week 2. Virus production was monitored twice a week by reverse transcriptase (RT) assay (60) .
Immunoblotting and antibody ELISAs. Cell lysates for immunoblotting were prepared as previously described (60) from HeLa cells transfected with infectious molecular clones of HIV-1 DH12 (1), SIV mac239 (50) , or SHIV MD1 (51) . Viral proteins were resolved on sodium dodecyl sulfate-polyacrylamide gels, transferred to nitrocellulose membranes, incubated with 1:50-diluted plasma from infected animals, and visualized with a Fuji phosphorimager (Fuji Medical System, Stamford, Conn.) after incubation with 125 I-protein A (ICN, Costa Mesa, Calif.). Binding antibodies in plasma were measured by enzyme-linked immunosorbent assay (ELISA), using an HIV-1 micro ELISA kit (Organon Teknika, Durham, N.C.), which employs HIV-1 particles as the antigen.
Quantitative DNA PCR. Proviral DNA copy numbers in cell lysates (PBMC and other tissues) were measured as previously described (49) . Fivefold dilutions of PBMC lysates (starting at 10 5 cell equivalents) were subjected to 30 cycles of DNA PCR in quadruplicate (94°C for 5 min; 30 cycles of 94°C for 45 s, 55°C for 45 s, and 72°C for 120 s; and 72°C for 7 min), using Ampli-Taq DNA polymerase (Perkin-Elmer, Norwalk, Conn.), followed by 30 cycles of nested PCR, and were analyzed on a 1% agarose gel. Since the distribution of amplifiable molecules in each dilution should follow the Poisson equation, P ϭ 1Ϫe∧(Ϫm), where P is the positive fraction and m is the average copy number, the dilution of PBMC at which 63.21% of the samples are PCR positive would correspond to a DNA copy number of one per sample. Such a dilution was calculated as described by Reed and Muench (46) . The detection limit of this assay is 3.1 copies of viral DNA/10 6 cells. Primers which are specific for SHIV (mapping to HIV-1 env gp120 coding sequences) and do not amplify SIV sequences are CTAAAGCCATGTGT AAAATTAACCCCACTC and TATAGAATTCACTTCTCCAATTGTCCCT CAT (used for the first PCR) and ACAGTACAATGTACACATGGAAT and CTGCCACATGTTTATAAATTGTTTTATTCTGCA (used for the nested PCR). Primers which detect SIV⌬2 and SIV⌬3 (mapping to the gp120 region of SIV env) and do not amplify HIV-1 sequences are ATAATTGCACAGGCTT GGAACAAGAGC and AAGTGTTGATTATTTGTCTAATATGACATGGC (used for the first PCR) and TGTGACAAACATTATTGGGATGCTATTAGA and TCCAATCGATACAGTTCTGCCACCTCTGCACT (used for the nested PCR).
RT-PCR. Virion RNA was prepared from 140 l of plasma by using an HCV kit (Qiagen, Chatsworth, Calif.). Fivefold dilutions of RNA samples (corresponding to 10 l of undiluted plasma) were amplified in quadruplicate by using rTh polymerase (Perkin-Elmer), which serves as both a thermostable RT and a thermostable DNA polymerase (50°C for 2 min; 60°C for 30 min; 30 cycles of 94°C for 45 s, 55°C for 45 s, and 72°C for 120 s; and 72°C for 7 min), followed by 30 cycles of nested DNA PCR using Ampli-Taq DNA polymerase (see above). The primers used map to the HIV-1 vpu gene and do not amplify SIV sequences; these primers are CTTAGGCATCTCCTATGGCAGGAAGAAGCGG and TACCCCATAATAGACTGTGACCCAC (used for the first RT-PCR) and CA AGCTTCTCTATCAAAGCAGTAAGTAGTAC and GCACTACAGATCAT CAATATCCCAAGGAGCA (used for the nested DNA PCR). The number of amplifiable RNA molecules was calculated as described above. The detection limit of the RT-PCR assay performed in this study was approximately 2,000 RNA copies/ml of plasma. The actual number of RNA molecules determined may have been underestimated, since the blood samples were processed 1 day following phlebotomy.
Neutralization assay. The SHIV MD1 stock used in neutralization experiments was generated in macaque PBMC and had a titer of approximately 20,000 TCID 50 /ml, which was remeasured prior to each assay. Plasma samples were serially diluted (threefold; from 3 Ϫ1 to 3 Ϫ5 ) in plasma from an uninfected macaque. A 20-l aliquot of each dilution was incubated with 20 l of undiluted SHIV at room temperature for 1 h and then used to infect MT-4 cells in quadruplicate; each culture (10 5 cells in 0.25-ml volume) was inoculated with 10 l of the virus-plasma mixture. Infected cultures were maintained for 2 weeks, and virus replication was monitored by RT assay; under these conditions, any infectious SHIV MD1 would be amplified to levels detectable by RT assay. In the experiment shown in Fig. 2B , 107 TCID 50 (determined from a titration experiment performed contemporaneously) of SHIV MD1 plus 5 l of serially diluted plasma was added to each well. In the assay shown in the right panel, the original dilution of plasma at which two of the four culture wells would be RT negative (neutralization positive) was calculated to be 3 Ϫ4. 33 by the method of Reed and Muench (46) . Since plasma had been further diluted 1:2 with virus stock containing 107 TCID 50 , the 50% neutralization titer against 100 TCID 50 The checkered boxes in the SIV⌬2 and SIV⌬3 genomes, both derivatives of SIV mac239 , denote mutations introduced for attenuation including 182 bp deleted from nef and 172 bp removed from the upstream U3 region the SIV⌬2 LTR (13) . SIV⌬3 has an additional 101-bp deletion in vpr (12) . The SHIV MD1 used in these experiments carries a portion of the U3 LTR, the R-U5 LTR, gag, pol, vif, and vpx, and approximately 20% of vpr from SIV mac239 . The remainder of vpr, tat, rev, env, and nef and a portion of the U3 LTR are derived from HIV-1; most of the HIV-1 sequences came from a T-cell/macrophage dual-tropic primary isolate HIV-1 DH12 (49) except for small segments at SIV-HIV-1 junctions (145 bp in vpr; 27 bp in nef) that were derived from HIV-1 NL43 (1). NRE, negative regulatory element.
was calculated to be 1:250 (3 Ϫ4.33 ϫ 2 ϫ 1.07). In this assay, a 1:4 dilution of plasma is the detection limit for neutralizing 100 TCID 50 of SHIV MD1 .
RESULTS
We examined the breadth of protection afforded by SIV vaccines against infection with a SHIV chimera, designated SHIV MD1 (46) , bearing the dual (T-cell line/macrophage)-tropic envelope glycoprotein of the primary HIV-1 isolate, HIV-1 DH12 (49) . As indicated in Fig. 1 , the tat, rev, vpu, env, and nef genes and most of the vpr gene of SHIV MD1 were derived from HIV-1.
A challenge virus stock (6 ϫ 10 4 TCID 50 /ml) was generated by passaging SHIV MD1 once in macaque PBMC and then recovering it from a cynomolgus monkey that had developed immunodeficiency (46) . In the experiments to be described, three rhesus macaques previously immunized with SIV⌬3 or SIV⌬2 (12) (Fig. 1) and two naive monkeys were intravenously inoculated with 30,000 TCID 50 of SHIV MD1 . On the day of challenge, the three vaccinated animals (7887, 42582, and 42982) had been infected with the attenuated SIVs for more than 4 years ( Table 1 ). The CD4 cell levels in the immunized animals were in the normal range; PBMC-associated SIV DNA was undetectable by nested PCR, and SIV⌬3 or SIV⌬2 could not be isolated by cocultivation. Furthermore, the PBMC from the vaccinated and naive animals were indistinguishable with respect to supporting SHIV infection in vitro or incorporating [ 3 H]thymidine following exposure to mitogen (data not shown). The plasma from the three immunized macaques contained antibody directed against SIV mac239 Gag and Env proteins as monitored by immunoblotting ( Fig. 2A, lanes  S) but not against the HIV-1 DH12 Env protein (lanes H and SH); reactivity against the SIV Gag protein component of the SHIV was also apparent. The absence of detectable antibody against HIV-1 proteins was also confirmed by ELISA in two of the three vaccinated animals; the third macaque (42582), however, had extremely high levels of ELISA antibody at all times examined and also reacted nonspecifically as assayed by Western blot analysis (compare lanes Cr and H in Fig. 2A, left) .
Because neutralizing antibodies directed against the parental HIV1 DH12 and its SHIV MD1 derivative are rapidly elicited and readily assayed in plasma from infected chimpanzees and macaques, respectively, samples were collected from the three SIV-vaccinated macaques and tested for neutralizing activity against SHIV MD1 . Serially diluted plasma from the immunized monkeys was incubated with approximately 100 TCID 50 of SHIV for 1 h, and the mixture was then tested for infectivity in MT-4 cells. As can be seen in Fig. 2B , plasma from a previously SHIV MD1 -infected animal neutralized SHIV MD1 through the fourth threefold dilution, whereas samples from SIV-vaccinated macaques 7887, 42582, and 43982 (not shown) did not exhibit any neutralization activity even at the lowest (1:3) dilution.
All five animals were challenged intravenously with 30,000 TCID 50 (5.5 ng of p27 antigen) of SHIV MD1 ; virus loads and antibody responses were monitored for 60 weeks. By a variety of criteria, all three SIV-vaccinated animals strongly resisted the SHIV infection, although sterilizing immunity was not achieved (Fig. 3) . Infectious SHIV was recovered from a single immunized animal (42582) on one occasion (week 6). In contrast, SHIV was isolated multiple times from the unvaccinated animals during the 8 weeks following virus inoculation and less frequently thereafter (Fig. 3A) . Similarly, SHIV DNA (amplified HIV-1 env sequences) was sporadically detected in the PBMC of vaccinated animals (the cutoff for detection was 3. ) plasma was incubated with 20 l of undiluted SHIV (approximately 20,000 TCID 50 /ml) at room temperature for 1 h and then used to infect MT-4 cells in quadruplicate; each culture received 10 l of virus-plasma mixture. In the experiment shown, 107 TCID 50 of SHIV MD1 plus 5 l of serially diluted plasma was added to each well. Cultures were kept for 2 weeks, and virus replication was visualized by autoradiography following RT assay. (Fig. 4) . d 50% neutralization titer against 100 TCID 50 of SHIV.
copies of viral DNA/10 6 cells), averaging less than 4.5 copies/ 10 6 cells during the entire observation period (Fig. 3B) . In contrast, the PBMC-associated SHIV DNA peaked at 1,000 to 2,000 copies/10 6 PBMC shortly after infection of the unvaccinated animals, averaging approximately 300 copies/10 6 cells during the 60-week study. The detection of SIV⌬3 or SIV⌬2 DNA in PBMC of the vaccinated and challenged macaques was also sporadic and present at levels similar to that of the PBMC-associated SHIV DNA (Fig. 3B, bottom) .
SHIV RNA in the plasma of the inoculated macaques was measured by amplifying vpu sequences by RT PCR. High levels of SHIV RNA, which peaked on week 2, were detected in the unvaccinated animals on multiple occasions during the first 5 weeks of SHIV infection. In contrast, significantly lower amounts of SHIV RNA were identified on single occasions in two of the three immunized macaques (7887 and 42582) and was never observed in the third (43982) animal. The limit of detection in our RT-PCR assays was approximately 2,000 RNA copies/ml of plasma.
Additional evidence supporting the potency of the attenuated SIV vaccine against a SHIV challenge was the very weak immune response directed against HIV-1 envelope proteins (Fig. 4A) . Following inoculation of SHIV MD1 , the two unimmunized macaques rapidly developed high titers (1:1875 in 24295; 1:9375 in 25095) of anti-HIV-1 ELISA antibody, whereas in two of the vaccinated animals, the antibody titer never exceeded 1:75, the detection limit of the commercial kit used. In the third immunized macaque (42582), it is unclear whether any elevation of the anti-HIV ELISA antibody levels occurred due to extremely high, and presumably nonspecific, reactivity existing prior to challenge (Table 1 ; Fig. 4A ). Following inoculation of SHIV, the plasma from animal 42582 continued to be unreactive with HIV-1 DH12 proteins by Western blot analysis (data not shown). Neutralization assays also confirmed the absence of an antibody response in the three vaccinated macaques (Fig. 4B) . In contrast to the two unimmunized animals which developed neutralizing antibodies against SHIV and HIV-1 DH12 (not shown) within 10 to 12 weeks, the plasma from the three vaccinated monkeys contained no detectable activity during the 60-week course of the experiment (Fig. 4B) .
Although, as noted earlier, the SHIV MD1 challenge stock was derived from a macaque that developed immunodeficiency, none of the infected animals in this study exhibited signs of disease. On week 60, one of the vaccinated macaques (42582) suddenly died. At necropsy, disseminated intravascular coagulation (DIC) was apparent; the DIC was characterized by multifocal thromboses affecting glomerular and renal parenchymal vessels, with associated hemorrhage and distortion of glomerular architecture. The DIC could not be attributed to any underlying neoplastic, lymphoproliferative, infectious, or cardiovascular disease process. Pathological changes usually associated with lentiviral induced immunodeficiency, including either hyperplasia or depletion of lymphocytes in lymphoid tissue or opportunistic infections, were not evident. As far as virus levels in monkey 42582 are concerned, SHIV could not be isolated from PBMC by cocultivation one week before death (week 60). Similarly, the week 60 plasma was negative (Ͻ2,000 RNA copies/l) for both SIV and SHIV RNA by RT-PCR. For all of these reasons, we believe that it is highly unlikely that the sudden death of macaque 42582 was caused by SHIV or SIV.
The study was terminated on week 61, at which time the four remaining animals were sacrificed and the tissue distribution of SHIV or SIV⌬3/SIV⌬2 DNA was determined by DNA PCR. In the two unvaccinated macaques, the SHIV DNA copy number was highest in lymph nodes and spleen and somewhat lower in PBMC (Fig. 5, left panels) . SHIV DNA was also detected in lung tissue from animal 25095, a frequent occurrence in macaques inoculated with HIV-1 DH12 -derived SHIV (46) . In contrast to this pattern of tissue distribution, SHIV DNA could not be amplified from lymph node specimens of the vaccinated animals (the detection limit is three copies of SHIV DNA/10 6 cells), although a spleen sample from macaque 43982 was positive (Fig. 5, right panels) . On the other hand, these same tissue specimens contained substantial amounts of SIV⌬3/SIV⌬2 DNA even though the average SHIV and SIV PBMC-associated virus loads were both low and comparable in the immunized macaques (Fig. 3) .
DISCUSSION
For several years, the capacity of a candidate vaccine to completely block the establishment of primate lentivirus infections in vivo was used as the principal standard for assessing efficacy. This was due, in part, to the belief that the integration step in the retrovirus life cycle had to be totally suppressed if disease was to be prevented. It is now recognized that even very effective live, attenuated lentiviral vaccines cannot completely block infection in all exposed individuals; however, virus loads may be substantially reduced and the onset of disease may be significantly delayed (44) . The latter parameters can be monitored by comparing virus isolations, levels of viral nucleic acids (plasma virus RNA; PBMC-associated viral DNA), and the clinical course in vaccinated and nonimmunized animals over extended periods of time. In this study, we used DNA PCR and RT-PCR, capable of distinguishing the vaccine from the challenge virus, to quantitate virus loads in plasma and PBMC (over a 60-week period) and in a variety of tissue samples collected at the conclusion of the experiment. By several criteria, SHIV concentrations were reduced to barely detectable levels both in the circulating blood and lymphoid tissues. In fact, two of the three vaccinated animals (43982 and 7887) could be viewed as being completely protected from infection, if, as was the case for similar previously reported studies of this type, only antibody responses and virus isolation were monitored.
Several groups have assessed the protective effects of attenuated vaccines in macaque monkeys against challenges with heterologous primate lentiviruses. In two such studies, animals chronically infected with nonpathogenic HIV-2 were superchallenged with pathogenic SIV sm intravenously (44) (59) . In the first, three of four cynomolgus monkeys remained disease free for more than 5 years following virus challenge, whereas no significant protective effect was observed in the second study. In three other studies, macaques persistently infected with nonpathogenic SHIVs were superchallenged with SIV sm intravaginally (45), SIV mac239 intravaginally (36), or SIV mac251 intravenously (30) . In all three studies, the SIVs were either never recovered or detected only sporadically compared to unvaccinated animals from which the challenge virus was readily isolated. Finally, in a study similar to ours in design that involved rhesus macaques vaccinated with the attenuated SIV BK28 and challenged with a SHIV bearing an env gene from HIV-1 HXB2 , suppression of SHIV replication was demonstrated by DNA PCR and RT-PCR, although this result was complicated by an unexplained decline of CD4 cells in the immunized animals compared to the control monkeys (6) . Although so-called sterilizing immunity by vaccination is rarely achievable especially against a heterologous lentivirus, reduction of virus loads could have a substantial effect on the clinical outcome: (i) HIV-1 loads early after infection have been shown to be a predictor of the clinical course in infected humans (18, 34, 38) ; and (ii) a recent SIV study has suggested the existence of a threshold of viral RNA levels in the plasma, below which disease is unlikely to occur (25) . It could be argued, therefore, that an ideal HIV-1 vaccine would be able to reduce the replication of HIV-1 field isolates to levels that would rarely result in disease; in the process, some individuals might even be protected from infection. This idea, however, raises several additional issues concerning the interpretation of vaccine experiments from animal models in which a variety of challenge viruses with different replication properties have been used. Some SIVs, such as uncloned SIV mac251 , spread rapidly in vivo and generate sustained high levels of virus progeny, making them refractory to many types of prophylactic vaccine approaches. On the other hand, it is far easier to protect animals from infection with viruses that replicate to only low levels in vivo. Ideally, the challenge virus used in experiments modelling potential prophylactic human vaccines should mimic HIV-1 with respect to the clinical and pathologic sequelae induced. However, even when such challenge viruses are used, several questions remain unanswered, including how to extrapolate the reductions of challenge virus loads, effected by vaccines in macaques, to humans at risk for HIV. We are obviously unable to directly translate the nearly 100-fold reduction of virus loads conferred by SIV attenuated vaccines against SHIV MD1 to HIV-1 infections of humans or whether protection against disease development would be observed following a challenge with pathogenic strains of SHIV. Nonetheless, our results are particularly informative because they indicate that demonstrable neutralizing activity is not required for protection and that the durability of resistance conferred by the SIV live, attenuated vaccine was greater than 4 years.
During the past 10 years of HIV-1/SIV vaccine research, considerable weight has been placed on (i) neutralizing antibodies as a possible correlate of immunologic protection and (ii) the ability of candidate prophylactic vaccines to elicit virus neutralizing antibodies an indicator of potential effectiveness FIG. 5 . Tissue distribution of viral DNA. Fresh tissues obtained at necropsy were minced to a single-cell suspension and analyzed by flow cytometry for cell surface markers (CD2, CD4, CD8, and CD20) to ascertain the presence of specific cell types. The percentage of CD4 cells is indicated on the left. The same procedure as used for Fig. 3 was used to estimate DNA copy numbers of SHIV (shaded bars) and SIV (black bars). Only lymph node (LN) samples from unvaccinated animals (24295 and 25095) were analyzed for the presence of SIV, and they were negative. BM, bone marrow. in vivo. Work in this area has focused primarily on the role of lentiviral envelope glycoproteins and peptides to elicit neutralizing activity; in this regard, the great heterogeneity of envelope glycoproteins associated with HIV-1 isolates of diverse origin (for a review, see reference 14) has raised concern about ever developing an effective prophylactic vaccine against the virus. It was therefore unexpected that the protected SIVvaccinated macaques had no preexisting neutralizing antibodies directed against SHIV, nor did they produce neutralizing antibodies at any time during the 14-month observation period following SHIV challenge. Contemporaneously conducted ELISA and immunoblotting assays also indicated that the live, attenuated SIV vaccine and the SHIV challenge of the immunized animals elicited very little, if any, antibody response against HIV-1 proteins.
Taken at face value, our results indicate that neutralizing antibodies directed against HIV-1 gp120 and gp41 did not contribute to the potent resistance elicited by SIV attenuated vaccines against the SHIV challenge. Although these experiments do not rule out cellular immune mechanisms (e.g., cytotoxic T lymphocytes) directed against conserved epitopes in the envelope proteins of HIV-1 and SIV, it is more likely that the observed protection involved immunologic targeting of the viral proteins shared between SIV and SHIV (such as Gag, Pol, Vif, and Vpx). Alternatively, nonimmunologic mechanisms (e.g., possible suppressive soluble factors interfering with virus entry or proviral DNA expression) might be playing a role in the protective effects observed. It could be argued, therefore, that (i) strategies for vaccine development be directed against other viral/cellular targets and (ii) attenuated subhuman primate lentiviruses be considered as a candidate live virus vaccine for prophylaxis against HIV-1 infection in humans.
